With tumor material obtained from individuals with resistance to checkpoint therapy enrolled in clinical trials at our center, we altered the tumor microenvironment (TME) of intact tumor fragments by incorporating anti-CTLA-4 or anti-PD-1 monoclonal antibodies directly into the culture medium and subsequently harvesting the outgrown TILs. The gene discussed is CTLA4; the disease is neoplasm.